Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC) Reckamp, K. L., Infante, J. R., Blumenschein, G. R., Wakelee, H., Carter, C. A., Gockerman, J. P., Lovly, C., Dukart, G., Harrow, K., Liang, C., Gibbons, J. J., Horn, L. ELSEVIER SCIENCE INC. 2016: S36–S37
View details for Web of Science ID 000427344900061